Sitemap Contact Newsfeed in RSS/RDF-Format Follow us on Twitter Visit us on Facebook Connect us in LinkedIn
Statistics
Online:23 Visitors
Today: 1224
Yesterday: 2520
Total: 613893

Sponsors

Lambert Instruments

QBC Diagnostigs

North89.com

CRAIC Technologies, Inc.

Märzhäuser Wetzlar stands for precision and quality

JENOPTIK


Newsletter
First Name:
Name:
Email:



Contact
  
    Internet Agency
    200 Barnes Lane
    Branson, MO 65616 - USA
     info@microscopy-news.com



Welcome to Microscopy-News.com
News


Sponsors



Leiden University uses NanoSight Characterization System to Aid Their Drug Delivery Research Programs

Salisbury, UK, 23rd February 2010: - The Division of Drug Delivery Technology is part of the Leiden/Amsterdam Center for Drug Research (LACDR), a research institute located at the Gorlaeus laboratories in Leiden in the Netherlands. The group focuses primarily on vaccine delivery and on protein formulation and characterization with respect to immunogenicity. Nanoparticle size and count is vital to these research activities and the Division has selected the NanoSight LM20 to aid their programs.

The leader of the team is Professor Wim Jiskoot. He describes what is important for his research: “The vaccine delivery group aims to develop innovative delivery systems, such as polymeric nanoparticles and liposomes, for the delivery of different types of vaccines through the conventional (injection) or needle-free administration routes (such as transcutaneous or intranasal delivery).

Professor Wim Jiskoot with Andrea Hawe and Vasco Filipe at Leiden University discuss results from the NanoSight LM20 system.

It is very important to know the size of the delivery systems as the size can influence the uptake by the cells of the immune system, the diffusion through the skin, the release of vaccine components, and thus the immune response.”

The protein characterization group seeks to understand the causes of unwanted immunogenicity of therapeutic proteins and develop transgenic mouse models capable of predicting immunogenicity of human/humanized proteins in a preclinical setting. Professor Jiskoot continues: “For the protein group, a good size characterization of protein aggregates is essential to better understand which size class is responsible for triggering unwanted immunogenicity of therapeutic proteins which is believed to be related to the presence of aggregates in the protein formulations. The group aims to stress and thoroughly characterize protein formulations to then test which ones are more immunogenic after their injection in the mouse models.”

Prior to using NanoSight’s LM20 system, the group used a variety of established particle characterization techniques such as Dynamic Light Scattering (DLS), Light Obscuration Particle Counting (LOPC) and Electron Microscopy (EM). However, each has deficiencies in terms of parameters such as sample preparation and speed of use. The main user is Vasco Filipe and he has seen several benefits which make the NanoSight his system of preference. “We are able to visualize the sample which gives us confidence in our results. Individual particle tracking enables a much better peak resolution than DLS so making it better suited to study polydispersed samples. It gives an approximate particle concentration while letting us see bacterial contamination easily as “swimming” particles.”

To learn more about nanoparticle characterization using Nanoparticle Tracking Analysis (NTA), please visit the company's website www.nanosight.com and register for the latest issue of NanoTrail, the company’s electronic newsletter.

About NanoSight
NanoSight Ltd, of Salisbury, UK, is the world leading provider of instruments for the optical detection and real time analysis of sub-micron particles. The Company supplies unique instruments for nanoparticle analysis in the sub-micron region that go far beyond existing light scattering techniques in the characterization of polydispersed systems. NanoSight delivers direct visualization of individual nanoscale particles in suspension from which independent quantitative estimation of particle size, size distribution and concentration are immediately obtained. In viral titer assessment, NanoSight produces more accurate concentration results than plaque assay, and delivers them within minutes, validating the results with a unique real-time image. Founded in 2004, the company currently has more than 200 systems in service worldwide, having begun commercial sales in 2006. The Company has a growing base of users worldwide, including BASF, BP GlaxoSmithKline, Novartis, 3M Corp, Roche, Solvay & Unilever and many universities. For more information, visit www.nanosight.com

For further information
Please contact NanoSight direct or their marketing agency, NetDyaLog Limited:

NanoSight Limited
Minton Park
London Road
Amesbury SP4 7RT
T +44 (0) 1980 676060
F +44 (0) 1980 624703
 www.nanosight.com
jeremy.warren@nanosight.com

NetDyaLog Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA
T +44 (0) 1799 521881
M +44 (0) 7843 012997
 www.netdyalog.com
jezz@netdyalog.com






generate PDF File  generate PDF File Print  Print

More News:
» Nikon Instruments Announces Popular Vote for 2010 Nikon Small World Competition
» UCLA, Japanese company to collaborate on specialized nano-imaging instrumentation
» Asylum Research and Harvard University Sponsor Free AFM Workshop Sept. 30-Oct. 1
» Carl Zeiss NTS GmbH - Senior Product Manager TEM (f/m)
» 2011 Workshop on FRET Microscopy - March 8-13, 2011 - Charlottesville, VA, USA
Home Contact Imprint Sitemap